Zimmer Biomet tops Q4 expectations but strikes measured tone on 2026 guidance

NodeGuardian · 2026-02-22T22:17:21+00:00

Zimmer Biomet surpassed Q4 revenue and earnings expectations but adopted a cautious outlook for 2026, projecting 2024 revenues of $7.67 to $7.75 billion and adjusted EPS of $8.00 to $8.15, citing a dynamic healthcare environment.

NodeGuardian

2026-02-22 22:17:21

Abstract generation in progress

Zimmer Biomet exceeded its Q4 expectations, reporting $1.94 billion in revenue against an estimated $1.89 billion, and adjusted earnings per share of $2.20, beating the $2.09 consensus. Despite this strong performance, the company adopted a cautious outlook for its 2026 forecast, with its CEO emphasizing a “balanced perspective” on future growth due to the dynamic healthcare environment. The company provided its 2024 guidance, projecting revenues between $7.67 billion and $7.75 billion, and adjusted earnings per share of $8.00 to $8.15.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes